Your browser doesn't support javascript.
loading
COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient.
Morita, Ryo; Kubota-Koketsu, Ritsuko; Lu, Xiuyuan; Sasaki, Tadahiro; Nakayama, Emi E; Liu, Yu-Chen; Okuzaki, Daisuke; Motooka, Daisuke; Wing, James Badger; Fujikawa, Yasunori; Ichida, Yuji; Amo, Kiyoko; Goto, Tetsushi; Hara, Junichi; Shirano, Michinori; Yamasaki, Sho; Shioda, Tatsuo.
Afiliação
  • Morita R; Department of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Kubota-Koketsu R; Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Lu X; Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Sasaki T; Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
  • Nakayama EE; Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Liu YC; Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Okuzaki D; Laboratory of Human Immunology (Single Cell Genomics), Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
  • Motooka D; Laboratory of Human Immunology (Single Cell Genomics), Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
  • Wing JB; Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
  • Fujikawa Y; Laboratory of Human Immunology (Single Cell Immunology), Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
  • Ichida Y; Department of Medical Laboratory, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Amo K; Department of Pharmacy, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Goto T; Department of Pediatric Emergency Medicine, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Hara J; Department of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Shirano M; Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Yamasaki S; Department of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Shioda T; Laboratory of Molecular Immunology, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
iScience ; 26(5): 106685, 2023 May 19.
Article em En | MEDLINE | ID: mdl-37124420
ABSTRACT
A 25-year-old patient with a primary immunodeficiency lacking immunoglobulin production experienced a relapse after a 239-day period of persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral genetic sequencing demonstrated that SARS-CoV-2 had evolved during the infection period, with at least five mutations associated with host cellular immune recognition. Among them, the T32I mutation in ORF3a was found to evade recognition by CD4+ T cells. The virus found after relapse showed an increased proliferative capacity in vitro. SARS-CoV-2 may have evolved to evade recognition by CD4+ T cells and increased in its proliferative capacity during the persistent infection, likely leading to relapse. These mutations may further affect viral clearance in hosts with similar types of human leukocyte antigens. The early elimination of SARS-CoV-2 in immunocompromised patients is therefore important not only to improve the condition of patients but also to prevent the emergence of mutants that threaten public health.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: IScience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: IScience Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão